Kventiax

Quetiapine, the active ingredient in Kventiax, is an atypical antipsychotic presented as an oral tablet for oral administration. It is used to manage symptoms of schizophrenia, to stabilize mood in bipolar disorder, and as an adjunctive treatment for major depressive disorder in adult patients requiring additional therapeutic support.

GNH USA supplies Kventiax as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under strict quality‑assurance standards. The company adheres to global regulatory requirements and offers reliable logistics for cross‑border distribution.

Quetiapine is an atypical antipsychotic that modulates neurotransmitter activity in several psychiatric disorders.

Schizophrenia: reduces psychotic symptoms such as delusions, hallucinations, and thought disorder. Bipolar disorder: helps control manic and depressive episodes, supporting mood stabilization. Major depressive disorder (adjunctive): enhances antidepressant response when added to standard therapy in patients with inadequate improvement.

Quetiapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Drowsiness or sedation - Dry mouth - Constipation - Weight gain

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Severe hypotension - QT interval prolongation, which may predispose to cardiac arrhythmias

When prescribing quetiapine, clinicians should consider several safety measures.

Dose titration: start low and increase gradually under medical supervision. Monitor metabolic parameters: regular checks of weight, glucose, and lipid levels. Assess for suicidal ideation: especially during early treatment or dose changes. Avoid abrupt discontinuation: taper gradually to reduce withdrawal symptoms. Caution in hepatic impairment: dose may need adjustment. Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Quetiapine interacts with several drug classes that may require dose adjustment or monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels and toxicity. - CNS depressants (e.g., alcohol, benzodiazepines): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Antihypertensives: additive orthostatic hypotension. - Antidiabetic agents: may affect glucose control.